Advertisement
NAMS vs PTCT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and PTCT is a StrongBuy.
NAMS's Indicator enters downward trend
The Aroon Indicator for NAMS entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator formed such a pattern. In 141 of the 166 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Indicator exited the oversold zone, 25 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NAMS as a result. In 67 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on October 20, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 38 of 57 cases over the following month. The odds of a continued upward trend are 67%.
Following a +8.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 199 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.085) is normal, around the industry mean (2.973). P/E Ratio (-9.991) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PTCT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
PTCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 41 cases where PTCT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PTCT's RSI Indicator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where PTCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on PTCT as a result. In 64 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for PTCT just turned positive on October 20, 2026. Looking at past instances where PTCT's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTCT advanced for three days, in 223 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 50-day moving average for PTCT moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for PTCT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-31.817) is normal, around the industry mean (2.973). PTCT has a moderately low P/E Ratio (-94.090) as compared to the industry average of (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.094) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. PTCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PTCT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 63 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 71 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| NAMS | PTCT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 81% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 78% | 9 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NAMS’s FA Score shows that 2 FA rating(s) are green while PTCT’s FA Score has 1 green FA rating(s).
- NAMS’s FA Score: 2 green, 3 red.
- PTCT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NAMS’s TA Score shows that 5 TA indicator(s) are bullish while PTCT’s TA Score has 6 bullish TA indicator(s).
- NAMS’s TA Score: 5 bullish, 3 bearish.
- PTCT’s TA Score: 6 bullish, 3 bearish.
Price Growth
NAMS (@Biotechnology) experienced а +7.40% price change this week, while PTCT (@Biotechnology) price change was +3.36% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
NAMS is expected to report earnings on Nov 04, 2026.
PTCT is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NAMS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with VKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then VKTX could also see price increases.
| Ticker / NAME | Correlation To NAMS | 1D Price Change % | ||
|---|---|---|---|---|
| NAMS | 100% | +0.42% | ||
| VKTX - NAMS | 45% Loosely correlated | -2.08% | ||
| IMVT - NAMS | 45% Loosely correlated | +2.54% | ||
| PTCT - NAMS | 43% Loosely correlated | +0.67% | ||
| KURA - NAMS | 42% Loosely correlated | -0.20% | ||
| RAPP - NAMS | 41% Loosely correlated | +5.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IXJ | 110.35 | 1.56 | +1.43% |
| iShares Global Healthcare ETF (IXJ) | |||
| FLQS | 48.99 | 0.61 | +1.27% |
| Franklin U.S. Small Cap Multifactor Index ETF (FLQS) | |||
| JUST | 109.41 | -1.24 | -1.12% |
| Goldman Sachs JUST U.S. Large Cap Equity ETF (JUST) | |||
| IEUS | 69.73 | -0.82 | -1.16% |
| iShares MSCI Europe Small-Cap ETF (IEUS) | |||
| ARVR | 56.80 | -1.12 | -1.94% |
| First Trust Indxx Metaverse ETF (ARVR) | |||